Related Experiment Video
Updated: Jun 8, 2026
04:14
Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis (NASH) Resolution
Published on: April 16, 2019
Early clinical studies with liraglutide
1Dept of Medicine I, St. Josef Hospital, Ruhr-University of Bochum Medical School, Bochum, Germany. Wolfgang.e.schmidt@ruhr-unibochum.de
International Journal of Clinical Practice. Supplement
|October 5, 2010
Summary
Liraglutide improved glycemic control and beta-cell function in early trials, offering a novel approach for type 2 diabetes management. It also promoted weight loss and improved cardiovascular risk factors with manageable side effects.
Area of Science:
- Pharmacology
- Endocrinology
- Metabolic Diseases
Background:
- Type 2 diabetes is a growing global health concern.
- Effective management requires addressing glycemic control, beta-cell function, and cardiovascular risk factors.
- Liraglutide is an emerging therapeutic agent for type 2 diabetes.
Purpose of the Study:
- To review Phase 1 and 2 clinical trials of liraglutide.
- To focus on the clinical pharmacology of liraglutide.
- To evaluate liraglutide's efficacy and safety in type 2 diabetes.
Main Methods:
- Review of early-phase clinical trials (Phase 1 and 2).
- Analysis of liraglutide's effects on glycemic control (HbA1c, FPG).
- Assessment of liraglutide's impact on beta-cell function, weight, and cardiovascular risk factors.
Main Results:
- Liraglutide (0.05-1.9 mg daily) improved glycemic control and beta-cell function.
- Significant reductions in HbA1c and FPG were observed.
- Clinically meaningful weight loss and improvements in cardiovascular risk factors were noted.
- Gastrointestinal side effects, primarily mild nausea, were reported.
Conclusions:
- Liraglutide demonstrates glucose-dependent glycemic control with a low risk of hypoglycemia.
- Liraglutide promotes weight loss and improves cardiovascular risk factors.
- Liraglutide represents a potentially valuable therapeutic option for type 2 diabetes management.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...